Last reviewed · How we verify
Chlorhexidine, immersion
Chlorhexidine, an antiseptic solution marketed by the University of Santiago de Compostela, holds a position in the healthcare market as a widely recognized and used product. A key strength is the protection afforded by a key composition patent, which expires in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Chlorhexidine, immersion |
|---|---|
| Also known as | Oraldine Perio |
| Sponsor | University of Santiago de Compostela |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Methodology Antiseptic Application, Influence on Oral Biofilm. (PHASE4)
- A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine, immersion CI brief — competitive landscape report
- Chlorhexidine, immersion updates RSS · CI watch RSS
- University of Santiago de Compostela portfolio CI